N4 Pharma PLC
LSE:N4P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.1), the stock would be worth GBX0.45 (0% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.1 | GBX0.45 |
0%
|
| 3-Year Average | 2.1 | GBX0.45 |
0%
|
| 5-Year Average | 2.6 | GBX0.55 |
+22%
|
| Industry Average | 0.1 | GBX0.01 |
-97%
|
| Country Average | 0 | GBX0 |
-99%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
N4 Pharma PLC
LSE:N4P
|
3.7m GBP | 2.1 | -3.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 30.3 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 5.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 5.9 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 5.2 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.9 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 1.7 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 6.3 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 49 422.3 |
Other Multiples
N4 Pharma PLC
Glance View
N4 Pharma Plc is a pharmaceutical company, which engages in the reformulation of existing drugs and vaccines. The company is headquartered in Derby, Derbyshire and currently employs 5 full-time employees. The company went IPO on 2005-06-07. The firm is engaged in engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company is focused on developing a delivery system for vaccines and cancer treatments using its silica nanoparticle delivery system called Nuvec. Nuvec is a non-viral adjuvant delivery system that has the potential to revolutionize vaccines and cancer treatments. The company is focused on development and commercialization of medicines via its delivery system.
